They said it was very likely that any FDA approval process for ST-246 will extend beyond the current BARDA contract. The good news is Siga might never recognize any revenues for litigation purposes (or taxes for that matter), so they'll never have anything to split with PIP, no matter what...LOL! The bad news is part of the current payment schedule under the current BARDA contract is contingent upon FDA approval for ST-246.
Say adios to that money...LOL!
Agreed. If you read between the lines, these morons know there is no way they're meeting that term in the contract and will realize the FDA approval monies. They basically straight out said it, if you know how to listen with a keen ear. If you paid attention, you'd have also taken away that they feel like there will be no further RPF for a smallpox drug. No confidence there at all. So, now we know why they're "OPTIMIZING". Problem with that is they, once AGAIN, only said it was "in process" and conversations were "happening". That could literally mean ANYTHING....like, hey, I placed a phone call to a guy at Merck and he told me to go screw myself. That was a conversation that happened. These guys are the best at camoflague and smoke screens.